Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes

The ACOSOG Z6051 Randomized Clinical Trial

Evidence about the efficacy of laparoscopic resection of rectal cancer is incomplete, particularly for patients with more advanced-stage disease.

Objective:  To determine whether laparoscopic resection is noninferior to open resection, as determined by gross pathologic and histologic evaluation of the resected proctectomy specimen. 

Design, Setting, and Participants:  A multicenter, balanced, noninferiority, randomized trial enrolled patients between October 2008 and September 2013. The trial was conducted by credentialed surgeons from 35 institutions in the United States and Canada. A total of 486 patients with clinical stage II or III rectal cancer within 12 cm of the anal verge were randomized after completion of neoadjuvant therapy to laparoscopic or open resection.

Interventions:  Standard laparoscopic and open approaches were performed by the credentialed surgeons.

Main Outcomes and Measures:  The primary outcome assessing efficacy was a composite of circumferential radial margin greater than 1 mm, distal margin without tumor, and completeness of total mesorectal excision. A 6% noninferiority margin was chosen according to clinical relevance estimation.

Results:  Two hundred forty patients with laparoscopic resection and 222 with open resection were evaluable for analysis of the 486 enrolled. Successful resection occurred in 81.7% of laparoscopic resection cases (95% CI, 76.8%-86.6%) and 86.9% of open resection cases (95% CI, 82.5%-91.4%) and did not support noninferiority (difference, −5.3%; 1-sided 95% CI, −10.8% to ∞; P for noninferiority = .41). Patients underwent low anterior resection (76.7%) or abdominoperineal resection (23.3%). Conversion to open resection occurred in 11.3% of patients. Operative time was significantly longer for laparoscopic resection (mean, 266.2 vs 220.6 minutes; mean difference, 45.5 minutes; 95% CI, 27.7-63.4; P < .001). Length of stay (7.3 vs 7.0 days; mean difference, 0.3 days; 95% CI, −0.6 to 1.1), readmission within 30 days (3.3% vs 4.1%; difference, −0.7%; 95% CI, −4.2% to 2.7%), and severe complications (22.5% vs 22.1%; difference, 0.4%; 95% CI, −4.2% to 2.7%) did not differ significantly. Quality of the total mesorectal excision specimen in 462 operated and analyzed surgeries was complete (77%) and nearly complete (16.5%) in 93.5% of the cases. Negative circumferential radial margin was observed in 90% of the overall group (87.9% laparoscopic resection and 92.3% open resection; P = .11). Distal margin result was negative in more than 98% of patients irrespective of type of surgery (P = .91).

Conclusions and Relevance:  Among patients with stage II or III rectal cancer, the use of laparoscopic resection compared with open resection failed to meet the criterion for noninferiority for pathologic outcomes. Pending clinical oncologic outcomes, the findings do not support the use of laparoscopic resection in these patients.

JAMA. 2015;314(13):1346-1355. doi:10.1001/jama.2015.10529.  Trial Registration  clinicaltrials.gov Identifier: NCT00726622

Authors: James Fleshman, MD1; Megan Branda, MS2; Daniel J. Sargent, PhD2; Anne Marie Boller, MD3; Virgilio George, MD4; Maher Abbas, MD5; Walter R. Peters Jr, MD6; Dipen Maun, MD7; George Chang, MD8; Alan Herline, MD9; Alessandro Fichera, MD10; Matthew Mutch, MD11; Steven Wexner, MD12; Mark Whiteford, MD13; John Marks, MD14; Elisa Birnbaum, MD11; David Margolin, MD15; David Larson, MD2; Peter Marcello, MD16; Mitchell Posner, MD10; Thomas Read, MD16; John Monson, MD17; Sherry M. Wren, MD18; Peter W. T. Pisters, MD8; Heidi Nelson, MD19

Author Affiliations:

1Baylor University Medical Center, Dallas, Texas 

2Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota 

3Northwestern University, Feinberg School of Medicine, Chicago, Illinois 

4Indiana University School of Medicine, Indianapolis 

5Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates 

6Boone Hospital Center, Columbia, Missouri 

7Franciscan St. Francis Health, Indianapolis, Indiana 

8MD Anderson Cancer Center, Houston, Texas 

9Vanderbilt University School of Medicine, Nashville, Tennessee 

10University of Chicago, Chicago, Illinois 

11Washington University, St Louis, Missouri 

12Cleveland Clinic–Weston, Weston, Florida 

13The Oregon Clinic, Oregon Health & Science University, Portland 

14Lankenau Hospital, Wynnewood, Pennsylvania 

15Ochsner Clinic, New Orleans, Louisiana 

16Lahey Clinic, Burlington, Massachusetts 

17University of Rochester, Rochester, New York 

18Stanford University, Palo Alto, California 

19Mayo Clinic 

More in Renal Cancer